Everything below concerns DAC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
trend predicted for rigid elastic spheres. Indeed, the Chapman–Enskog analysis shows that the predicted temperature dependence can be tuned by varying the parameters in various molecular models. A simple example is the Sutherland model, which describes rigid elastic spheres with weak mutual attraction. In such a case, the attractive force can be treated perturbatively, which leads to a simple expression for
=== United States political and diplomatic figures === Philip Van Cortlandt (1758), soldier, statesman, U.S. congressman from New York Anthony Hoffman (1760), member of the New York State Senate Gilbert Livingston (1760), member of the New York Provincial Congress Gulian Verplanck (1768), speaker of the New York State Assembly; president of the Bank of New York 1791–1799 Philip Pell (1770), delegate for New York to the Congress of the Confederation Richard Varick (King's 1776), mayor of New York City and American Revolutionary War figure; aide-de-camp of Benedict Arnold and private secretary of George Washington David A. Ogden (178-), U.S. congressman from New York DeWitt Clinton (1786), governor of New York who initiated the construction of the Erie Canal; also served as United States senator from New York James Cochran (1788), U.S. congressman from New York Daniel C. Verplanck (1788), U.S. congressman from New York John Peter Van Ness (1789), U.S. congressman from New York and mayor of Washington, D.C. George Graham (1790), acting U.S. secretary of war under James Madison and James Monroe; commissioner of the General Land Office 1823–1830 John Graham (1790), secretary of the Orleans Territory; U.S. minister to Portugal; acting United States secretary of state in 1817 Jotham Post Jr. (1792), U.S. congressman from New York John Randolph of Roanoke* (1792), planter, U.S. congressman from Virginia, United States Senate from Virginia, U.S. ambassador to Russia; founder of the American Colonization Society George Clinton Jr. (1793), brother of DeWitt Clinton, and U.S.
The Green Book, formally titled Quantities, Units and Symbols in Physical Chemistry, is a compilation of terms and symbols widely used in the field of physical chemistry. It also includes a table of physical constants, tables listing the properties of elementary particles, chemical elements, and nuclides, and information about conversion factors that are commonly used in physical chemistry. The most recent is the third edition (ISBN 978-0-85404-433-7), originally published by IUPAC in 2007. A second printing of the third edition was released in 2008; this printing made several minor revisions to the 2007 text. A third printing of the third edition was released in 2011. The text of the third printing is identical to that of the second printing.
Sources: en.wikipedia.org
== Biological function == Inositol, phosphatidylinositol, and some of their mono- and polyphosphates function as secondary messengers in a number of intracellular signal transduction pathways. They are involved in a number of biological processes, including:
Spontaneous fission, discovered in 1940 by Georgy Flyorov, Konstantin Petrzhak, and Igor Kurchatov, is fission not induced by an exogenous neutron, but rather a spontaneous radioactive decay occurring because the nucleus is already unstable from an overabundance of neutrons, and occurs in very high-mass-number isotopes. In contrast to nuclear fusion, which powers stars and has created all the elements of the universe, (see iron peak) one can consider nuclear fission as negligible for the evolution of the universe. Nonetheless, natural nuclear fission reactors have formed under very rare conditions.
=== Phase 1 === ABL-301 (SAR-446159) – bispecific antibody against α-synuclein [72] ALS-205 (PMX-205) – complement C5a receptor antagonist [73] ALX-001 (BMS-984923) – metabotropic glutamate mGlu5 receptor silent allosteric modulator [74] ARV-102 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [75] ATH-399A (DWP-307399; HL-192) – nuclear receptor subfamily 4 group A member 2 (NR4A2) agonist [76] CT-2500 – undefined mechanism of action [77] FB-418 – Bcr-Abl tyrosine kinase inhibitor and leucine-rich repeat kinase 2 (LRRK2) inhibitor [78] GT-02287 – β-glucocerebrosidase (GCase) activator and/or chaperone [79] HL-400 – NLR family pyrin domain containing 3 (NLRP3) inhibitor [80] HNC-364 (rasagiline prodrug) – monoamine oxidase B (MAO-B) inhibitor [81] Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology (hAECs; hAESCs) – cell replacement [82] JNJ-0376 – undefined mechanism of action [83] JX-2105 – undefined mechanism of action [84] Lu AF28996 (Lu AF-28996) – dopamine D1 and D2 receptor agonist [85] LY-3962681 – RNA interference and α-synuclein expression modulator [86] MEDI-1341 (TAK-341) – monoclonal antibody against α-synuclein [87] NEU-723 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [88] NN-9001 – undefined mechanism of action [89] PK-081 – α-synuclein degrader [90] Selnoflast (NLRP3i; RG-6418; RO-7486967; Somalix) – NLR family pyrin domain containing 3 (NLRP3) inhibitor inhibitor [91] TRN-501 – undefined mechanism of action [92] VQ-101 – glucosylceramidase stimulant [93] WID-2301 – undefined mechanism of action [94] WIT-2001 – undefined mechanism of action [95]
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.